Redesigned MabThera for Treatment of ALS
News May 26, 2017 | Original Story from Ben-Gurion University of the Negev
Dr. Rachel Lichtenstein, Ben-Gurion University of the Negev
Ben-Gurion University of the Negev (BGU) researchers are developing a new therapy for Amyotrophic Lateral Sclerosis (ALS) using part of an existing FDA-approved drug that restores the central nervous system’s (CNS) immune defenses and increases life expectancy.
ALS, also known as Lou Gehrig’s disease, is a lethal, progressive neurodegenerative disorder that affects the motor nerve cells in both the brain and the spinal cord.
The progressive degeneration of motor neurons leads to atrophy, paralysis and eventually death due to failure of the respiratory muscles.
Since the exact cause of ALS is unknown, current research has focused on extending the post-onset life expectancy, which is currently between two to five years for most patients.
Part of the disease’s progression is linked to increased activity of glial cells, a type of immune cell that damages and kills the body’s motor neuron cells and decreases their ability to cleanse the CNS environment.
Dr. Rachel Lichtenstein of the Avram and Stella Goldstein-Goren Department of Biotechnology Engineering at BGU has focused on reducing this negative immune response. “We found a way to thwart the glial cells from attacking and killing healthy brain cells,” says Dr. Lichtenstein.
She successfully redesigned a portion of MabThera, an FDA-approved drug used to treat certain autoimmune diseases and types of cancer, into a new molecule to treat ALS.
“Our experimental results on ALS transgenic mice showed a significant increase in life expectancy”, says Dr. Lichtenstein. “Since the drug is already approved, we believe that we will only need limited preclinical testing to reach the clinical phase earlier than other initiatives.”
“This could also have major implications on the life expectancy of other neurodegenerative disease patients with Alzheimer’s and Parkinson’s,” says Dr. Ora Horovitz, senior vice president of business development at BGN Technologies, BGU’s technology transfer and commercialization company. “Our new drug candidate may prove effective in boosting the self-cleansing mechanism of the human brain, thereby improving the lives of millions of people.” The researchers are now seeking a pharmaceutical company partner.
Currently, there are only two drugs available for ALS patients: Reluzole (Rilutek), which helps extend patient survival by only three to six months; and the recently FDA- approved Edaravone (Radicava), which has demonstrated relatively modest success.
This article has been republished from materials provided by Ben-Gurion University of the Negev. Note: material may have been edited for length and content. For further information, please contact the cited source.